Glenmark Gets CDSCO panel nod for Phase IV CT of Fosnetupitant, Palanosetron FDC drug
Advertisement
New Delhi: Pharmaceutical major Glenmark Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) to conduct the Phase IV clinical trial for the fixed-dose combination drug Fosnetupitant 235 mg and Palanosetron 0.25mg used as a prophylactic regimen to prevent vomiting after the chemotherapy.
This came after the firm presented the Phase IV clinical trial protocol (Protocol No.GPL/CT/2022/008/IV, version: 2.0 dated 07-Dec-2022 before the committee.
At the recent SEC meeting for Oncology and Hematology held on 19th January 2023, the expert panel reviewed the Phase IV clinical trial protocol of the drug Fosnetupitant 235 mg and Palanosetron 0.25mg (Concentrate for solution for infusion) presented by the drug major Glenmark Pharmaceutical.
After detailed deliberation, the committee recommended the grant of permission to conduct the Phase IV clinical trial as per the submitted protocol.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.